The Belinostat Z-Isomer is a stereoisomeric impurity of the active pharmaceutical ingredient (API) Belinostat.

Used to detect, identify, and quantify cis-trans (Z/E) isomerization that may occur during synthesis or storage.

Ensures isomeric purity, which is critical for drug efficacy and safety.

Serves as a reference standard for the development of stereoselective and stability-indicating methods such as:

• HPLC with chiral or stereospecific columns

• LC-MS/MS

• UPLC

Validates analytical parameters like:

• Specificity

• Resolution between E- and Z-isomers

• Linearity, LOD, and LOQ

Supports regulatory submissions under:

• ICH Q3A/B guidelines for impurity profiling

• FDA, EMA, and other agency requirements related to stereochemical characterization

Required in:

• ANDA filings

• DMF submissions

• CTD dossiers

Used in forced degradation and photostability studies to evaluate:

• Potential Z-isomer formation under stress conditions (e.g., UV light, heat)

• Isomeric stability during shelf-life and formulation storage

Implemented in routine QC testing to monitor levels of the Z-isomer in Belinostat bulk and dosage forms.

Ensures regulatory compliance by maintaining the Z-isomer within acceptable thresholds.

Used in synthetic chemistry and drug development labs to:

• Study isomerization mechanisms

• Optimize reaction conditions to minimize Z-isomer formation

• Understand the structure-activity relationship (SAR) of stereoisomers

Belinostat Amide is commonly identified as a synthetic intermediate or process-related impurity of the anti-cancer drug Belinostat.

Used as a reference standard for:

• Monitoring impurities in Belinostat API and formulations

• Ensuring product purity and batch consistency

Crucial in the development of stability-indicating analytical methods such as:

• HPLC

• UPLC

• LC-MS/MS

Supports:

• Specificity testing to differentiate Belinostat Amide from the parent drug

• Establishing LOD/LOQ, linearity, and accuracy for impurity quantification

Required for regulatory submissions such as:

• ANDA, DMF, and CTD dossiers

• Supports compliance with ICH Q3A/B guidelines for impurity qualification

Helps justify impurity levels and contributes to establishing acceptable impurity limits

Used in forced degradation studies to evaluate the formation of Belinostat Amide as a potential degradation product.

Aids in determining the stability profile of Belinostat under various conditions (light, heat, oxidative stress)

Implemented in routine QC testing for:

• Release of Belinostat API and finished products

• Tracking impurity levels in accordance with pharmacopeial or internal specifications

Applied in:

• Process development and optimization studies for Belinostat manufacturing

• Structure elucidation and impurity pathway analysis

• Pharmaceutical formulation research

Belinostat Impurity 1 is a known process or degradation impurity of the oncology drug Belinostat.

Used to identify, quantify, and characterize impurity levels in Belinostat API and finished dosage forms.

Essential for creating stability-indicating analytical methods such as:

• HPLC

• UPLC

• LC-MS/MS

Assists in validating:

• Specificity (distinguishing impurity from the main compound)

• LOD/LOQ (Limit of Detection/Quantification)

• Linearity, accuracy, and precision

Used for regulatory submissions such as:

• ANDA, DMF, and CTD dossiers

• Supports ICH Q3A/B requirements for impurity limits and qualification

Provides toxicological data support when required for threshold exceedance.

Involved in forced degradation testing to track impurity formation under stress conditions (light, heat, humidity, pH).

Helps establish the impurity profile and contributes to shelf-life determination.

Used in routine quality control labs for:

• In-process monitoring

• Batch release testing of Belinostat

• Ensuring regulatory compliance and batch consistency

Supports synthetic route optimization and mechanistic impurity formation studies.

Applied in CROs, pharmaceutical R&D labs, and academic research for advanced impurity mapping.

Belinostat Acid is commonly known as a process-related or degradation impurity of the anti-cancer drug Belinostat.

It is used as a reference standard to identify, quantify, and control impurities in:

• Belinostat API

• Belinostat formulations (injection, capsules, etc.)

Plays a crucial role in the development and validation of analytical methods such as:

• HPLC

• UPLC

• LC-MS/MS

Supports:

• Specificity testing – ensuring separation of Belinostat Acid from the parent compound

• Determining LOD/LOQ for impurity analysis

• Linearity, accuracy, and robustness validation for impurity detection

Used in forced degradation studies to track the formation of Belinostat Acid as a potential oxidative or hydrolytic degradation product.

Helps map degradation pathways, essential for:

• Establishing product shelf life

• Ensuring formulation stability

• Understanding stress behavior of Belinostat

Required in regulatory submissions (e.g., ANDA, DMF, CTD) for:

• ICH Q3A/Q3B compliance

• Setting impurity limits

• Justifying impurity qualification and toxicology assessments

Applied in routine QC and batch testing to monitor impurity levels in Belinostat API and drug products.

Ensures batch-to-batch consistency and helps meet regulatory release specifications.

Useful in R&D labs and CROs for:

• Investigating Belinostat’s synthetic process optimization

• Studying metabolite or intermediate formation

• Supporting analytical and toxicological research

Belinostat is an FDA-approved histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancers, particularly:

• Peripheral T-cell lymphoma (PTCL)

• Other hematologic malignancies and solid tumors (in clinical studies)

Used to study epigenetic modulation in cancer cells, helping researchers explore gene expression regulation and tumor suppression mechanisms.

Employed as a reference standard in the development, validation, and quality control of Belinostat-based pharmaceutical formulations.

Utilized for:

• Assay standardization

• Impurity profiling

• Stability testing

• Method validation (HPLC, LC-MS/MS, etc.)

A key tool in epigenetic drug screening and mechanistic studies involving:

• Chromatin remodeling

• Cell cycle arrest

• Apoptosis induction in tumor cells

Facilitates research on the HDAC inhibition pathway, offering insights into cancer proliferation and differentiation.

Used in in vitro and in vivo studies for:

• Evaluating anti-cancer activity

• Assessing pharmacokinetics and pharmacodynamics

• Understanding dose-response and toxicity profiles

Supports pharmaceutical R&D teams in designing oral or injectable dosage forms.

Helps in:

• Developing bioanalytical methods for pharmacokinetic studies

• Forced degradation and stability-indicating studies

• Establishing analytical quality-by-design (AQbD) approaches

Belinostat is investigated in combination therapies with other chemotherapeutic agents, immunotherapies, or targeted therapies.

Supports studies aiming to:

• Enhance therapeutic efficacy

• Overcome drug resistance in cancers

• Personalize cancer treatment based on epigenetic markers